Why RFK Can’t Stop Big Pharma

Some of the biggest gains during... ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

Practical Investment Analysis for the New Energy Economy Why RFK Can’t Stop Big Pharma Jeff Siegel | Nov 25, 2024 Vaccine Stocks made us a lot of money at the height of COVID. Indeed, we found no joy in exploiting that deadly pandemic or the draconian measures that were put in place for “our safety.”  Many of which turned out to be complete bullshit. But we don’t make the rules.  We profit from them.  And in a major way. Some of the biggest gains during the COVID years came from vaccine stocks such as Biontech (NASDAQ: BNTX), Moderna (NASDAQ: MRNA) and Novovax (NASDAQ: NVAX).  And when I say “big,” I’m not exaggerating.  Some of our readers had the opportunity to pull in massive gains from those. Take a look... BNTX — 421% gain MRNA — 2,150% gain NVAX — 3,524% gain And there were plenty more.  That’s just a small sampling. But some investors are worried that these vaccine stocks are going to take a hit now that Trump has appointed RFK, Jr. as the Secretary of Health and Human Services.  After all, the man has been highly critical of vaccines in the past.  The concern is that if he is approved, he would do everything in his power to derail vaccine protocols in the U.S.  But that’s not going to happen. The #1 Trump Trade for 2025 ISN'T Bitcoin... Bitcoin hit $93,000 after Trump’s win — and it’s set to soar much higher. But there’s a better way to profit from Trump’s Bitcoin boom — without owning a single coin or ETF. This secret play has outpaced Bitcoin by 11.5x, and you can get started with just $25. Get all the details on the #1 Trump Trade here. Vaccine stocks aren’t going anywhere Love him or hate him, Donald Trump responds to money and power.  Nothing else.  And while RFK would have some power serving in the Trump administration, he’ll never have the money and power Big Pharma has. Indeed, there is a very real problem in healthcare today.  And some of that is related to Big Pharma’s influence when it comes to healthcare policy.  The major pharma companies operating in the U.S. have spent billions of dollars over the years in an effort to influence policy.  And they’ve been hugely successful.  Unfortunately, however, sometimes at the expense of our collective health. Truth is, we spend more on healthcare than any other high-income country in the world, but have lower life expectancies.  Take a look... It’s no wonder there’s so much animosity towards Big Pharma in this country.  And while I’m not the kind of person who eschews western medicine (and I’m grateful for access to many of the pharmaceuticals available to us today), to assume that the Big Pharma machine can be derailed by an anti-vaccine Trump appointee would be foolish. I should point out, by the way, that I applaud RFK’s focus on healthy foods and exercise as a reliable solution to many of the chronic diseases that plague our nation.  Obesity, heart disease, diabetes.  These are all chronic diseases that, for the most part, can be treated and even cured by eschewing unhealthy foods and a sedentary lifestyle.  But I don’t buy for one second that his criticisms of vaccines are going to somehow get Big Pharma to throw in the towel.  After all, vaccines are big business. Tiny $3 Stock Delivers an AI Death Blow to Nvidia  TRADE ALERT ENCLOSED: CLICK HERE for the SHORT 5-MINUTE VIDEO...  Even if you remove COVID vaccines from the equation, pharmaceutical companies rake in tens of billions of dollars every year from the sale of vaccines alone.  To be sure, I’m not anti-vax at all.  I’m actually happy that I live in a country where Polio and Measles are about as common as toasting forks and buggy whips.  But you simply can’t deny that with billions of dollars worth of vaccines being questioned, Big Pharma will just sit back and do nothing. I don’t say this to criticize those who question the ethics of vaccines.  Particularly after what we witnessed with COVID.  I’m merely pointing out a truism that shouldn’t be lost on investors: Big Pharma is far more powerful than RFK will ever be.  And that, dear reader, is why you shouldn’t be too concerned about vaccine stocks getting pummeled in 2025. That being said, as we head into 2025, I’m not particularly focused on vaccine stocks.  There’s just so many other opportunities out there to make a lot more money.  Like this oil & gas tech company that just created a new drill which allows oil companies to increase output without drilling additional wells.  It’s like getting two oil wells for the price of one.   And with Trump’s pick for Energy Secretary — who’s a big oil & gas guy — the timing couldn’t be better for this stock. Which is why I’m including this new report we just published called the Trillion-Dollar Drill.  In it, you’ll see exactly how this technology works, why Big Oil loves it, and of course, learn the name of the stock. While there may be a little hesitation on vaccine stocks right now, it’ll likely pass.  But there’s zero hesitation on this Trillion-Dollar Drill stock.  Which is why I recommend you get some of this action for yourself — right now. To a new way of life and a new generation of wealth... Jeff Siegel Check us out on YouTube! @JeffSiegel on Twitter Jeff is the founder and managing editor of Green Chip Stocks. For more on Jeff, go to his editor's page. Want to hear more from Jeff? Sign up to receive emails directly from him ranging from market commentaries to opportunities that he has his eye on.  This email was sent to edwardlorilla1986.paxforex@blogger.com. You can manage your subscription and get our privacy policy here. Energy and Capital, Copyright © 3 East Read Street, Baltimore, MD 21202. Please note: It is not our intention to send email to anyone who doesn't want it. If you're not sure why you're getting this e-letter, or no longer wish to receive it, get more info here, including our privacy policy and information on how to manage your subscription. If you are interested in our other publications, please call our customer service team at 1-877-303-4529.